Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
ClinicalTrials.gov |
Last refreshed on:
|
15 August 2022 |
Main ID: |
NCT03118674 |
Date of registration:
|
13/04/2017 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
Harvoni Treatment Porphyria Cutanea Tarda
|
Scientific title:
|
Newer Direct-Acting Anti-Viral Agents as Sole Therapy of Porphyria Cutanea Tarda in Subjects With Chronic Hepatitis C |
Date of first enrolment:
|
September 6, 2017 |
Target sample size:
|
22 |
Recruitment status: |
Completed |
URL:
|
https://clinicaltrials.gov/show/NCT03118674 |
Study type:
|
Interventional |
Study design:
|
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
|
Phase:
|
Phase 2
|
|
Countries of recruitment
|
United States
| | | | | | | |
Contacts
|
Name:
|
Sean Rudnick, MD |
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
Wake Forest University Health Sciences |
|
Name:
|
Herbert L Bonkovsky, MD |
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
Wake Forest University Health Sciences |
| |
Key inclusion & exclusion criteria
|
Health Condition(s) or Problem(s) studied
|
Source(s) of Monetary Support
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|